Alzamend Neuro Inc
ALZN
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.21M
Close$
$0.21
85.4% downside
Current Fair Value
85.4% downsideOvervalued by 85.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.21 Million |
|---|---|
| Enterprise Value | $4.50 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.63 |
| Beta | 0.19 |
| Outstanding Shares | 3,337,143 |
Return
| Return on Equity | -1196.43% |
|---|---|
| Return on Assets | -421.88% |
| Return on Invested Capital | -1199.45% |
Valuation & Multiples
| P/E Ratio | -0.47 |
|---|---|
| PEG | -0.31 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.51 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 28, 2026
EPS Estimate
$-0.67
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
September 9, 2026
EPS Estimate
$-0.67
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 3.04%▼ 3.42% |
|---|---|
| Total Invested | $122,410▼ 72.63% |
| Investors Holding | 12▼ 1.00% |
ESG Score
No data
About Alzamend Neuro Inc
3 employees